Atogepant for the prevention of episodic migraine in adults
Objective: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods: The authors performed a systematic search for sources, including articles, abstracts, and poster presentations. Quer...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/20503121221128688 |
| _version_ | 1798021047694393344 |
|---|---|
| author | Maranda Paige Switzer Joseph Edward Robinson Kayla Rena Joyner Kelsey Woods Morgan |
| author_facet | Maranda Paige Switzer Joseph Edward Robinson Kayla Rena Joyner Kelsey Woods Morgan |
| author_sort | Maranda Paige Switzer |
| collection | DOAJ |
| description | Objective: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods: The authors performed a systematic search for sources, including articles, abstracts, and poster presentations. Queried databases were the National Institute of Health, US National Library of Medicine Clinical Trials, PubMed, European PMC, and the Cochrane Library. Search terms included atogepant, QULIPTA™, AGN-241689, MK-803, and N02CD07. Full-text, English language, randomized-controlled trials from 1 February 2012 to 1 February 2022 were included in the review. Additional relevant prescribing information, abstracts, and articles identified through the search were considered for inclusion in this review. A total of 193 database entries were evaluated for inclusion in this narrative review. Three articles representing two randomized controlled trials were reviewed. Results and conclusions: Atogepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is a daily oral treatment for migraine prevention. In placebo-controlled clinical trials, atogepant decreased mean monthly migraine days (MMD) over 12 weeks in patients with episodic migraine. Major treatment-related adverse effects include nausea and constipation. Long-term placebo-controlled efficacy and safety studies, chronic migraine studies, and studies in patients that failed more than two classes of preventive therapies are still pending. Atogepant represents one of many novel therapies for the prevention of migraine. To date, no head-to-head comparisons of atogepant versus other agents indicated for migraine prevention have been published. Atogepant offers patients an alternative therapy to injectable or infusion monoclonal antibody treatments and offers an alternative to non-specific migraine medications that are associated with poor tolerability. Due to its high cost and narrower therapeutic indications, atogepant may be reserved for a small subset of migraineurs who prefer oral therapy. |
| first_indexed | 2024-04-11T17:07:41Z |
| format | Article |
| id | doaj.art-0cb415f0e6654f28a3c843d64c0459f9 |
| institution | Directory Open Access Journal |
| issn | 2050-3121 |
| language | English |
| last_indexed | 2024-04-11T17:07:41Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medicine |
| spelling | doaj.art-0cb415f0e6654f28a3c843d64c0459f92022-12-22T04:12:59ZengSAGE PublishingSAGE Open Medicine2050-31212022-10-011010.1177/20503121221128688Atogepant for the prevention of episodic migraine in adultsMaranda Paige Switzer0Joseph Edward Robinson1Kayla Rena Joyner2Kelsey Woods Morgan3Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USABernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USAValley Health Winchester Medical Center, Winchester, VA, USAValley Health Winchester Medical Center, Winchester, VA, USAObjective: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods: The authors performed a systematic search for sources, including articles, abstracts, and poster presentations. Queried databases were the National Institute of Health, US National Library of Medicine Clinical Trials, PubMed, European PMC, and the Cochrane Library. Search terms included atogepant, QULIPTA™, AGN-241689, MK-803, and N02CD07. Full-text, English language, randomized-controlled trials from 1 February 2012 to 1 February 2022 were included in the review. Additional relevant prescribing information, abstracts, and articles identified through the search were considered for inclusion in this review. A total of 193 database entries were evaluated for inclusion in this narrative review. Three articles representing two randomized controlled trials were reviewed. Results and conclusions: Atogepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is a daily oral treatment for migraine prevention. In placebo-controlled clinical trials, atogepant decreased mean monthly migraine days (MMD) over 12 weeks in patients with episodic migraine. Major treatment-related adverse effects include nausea and constipation. Long-term placebo-controlled efficacy and safety studies, chronic migraine studies, and studies in patients that failed more than two classes of preventive therapies are still pending. Atogepant represents one of many novel therapies for the prevention of migraine. To date, no head-to-head comparisons of atogepant versus other agents indicated for migraine prevention have been published. Atogepant offers patients an alternative therapy to injectable or infusion monoclonal antibody treatments and offers an alternative to non-specific migraine medications that are associated with poor tolerability. Due to its high cost and narrower therapeutic indications, atogepant may be reserved for a small subset of migraineurs who prefer oral therapy.https://doi.org/10.1177/20503121221128688 |
| spellingShingle | Maranda Paige Switzer Joseph Edward Robinson Kayla Rena Joyner Kelsey Woods Morgan Atogepant for the prevention of episodic migraine in adults SAGE Open Medicine |
| title | Atogepant for the prevention of episodic migraine in adults |
| title_full | Atogepant for the prevention of episodic migraine in adults |
| title_fullStr | Atogepant for the prevention of episodic migraine in adults |
| title_full_unstemmed | Atogepant for the prevention of episodic migraine in adults |
| title_short | Atogepant for the prevention of episodic migraine in adults |
| title_sort | atogepant for the prevention of episodic migraine in adults |
| url | https://doi.org/10.1177/20503121221128688 |
| work_keys_str_mv | AT marandapaigeswitzer atogepantforthepreventionofepisodicmigraineinadults AT josephedwardrobinson atogepantforthepreventionofepisodicmigraineinadults AT kaylarenajoyner atogepantforthepreventionofepisodicmigraineinadults AT kelseywoodsmorgan atogepantforthepreventionofepisodicmigraineinadults |